CN102600091B - 一种盐酸伊托必利分散片组合物 - Google Patents
一种盐酸伊托必利分散片组合物 Download PDFInfo
- Publication number
- CN102600091B CN102600091B CN201210086799.1A CN201210086799A CN102600091B CN 102600091 B CN102600091 B CN 102600091B CN 201210086799 A CN201210086799 A CN 201210086799A CN 102600091 B CN102600091 B CN 102600091B
- Authority
- CN
- China
- Prior art keywords
- itopride hydrochloride
- dispersible tablet
- tablet composition
- itopride
- polyvinylpolypyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229960005302 itopride Drugs 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 32
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 19
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims abstract description 19
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 19
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 18
- 239000008101 lactose Substances 0.000 claims abstract description 18
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 16
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 16
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 16
- 239000001923 methylcellulose Substances 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 16
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 16
- 239000003826 tablet Substances 0.000 claims description 17
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 15
- 229950005770 hyprolose Drugs 0.000 claims description 15
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 15
- 239000006185 dispersion Substances 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 239000008187 granular material Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 229920003091 Methocel™ Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960004076 secnidazole Drugs 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000131329 Carabidae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical group CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
实施例1 | 实施例2 | 实施例3 | 实施例4 | 对照例1 | 对照例2 | |
分散时间 | 1分9秒 | 1分18秒 | 1分20秒 | 1分22秒 | 2分6秒 | 1分52秒 |
外观 | 无麻面 | 无麻面 | 无麻面 | 无麻面 | 轻微麻面 | 麻面 |
溶出度% | 99.7 | 100.5 | 99.0 | 98.9 | 90.3 | 87.9 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210086799.1A CN102600091B (zh) | 2012-02-13 | 2012-03-21 | 一种盐酸伊托必利分散片组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210035444 | 2012-02-13 | ||
CN201210035444.X | 2012-02-13 | ||
CN201210086799.1A CN102600091B (zh) | 2012-02-13 | 2012-03-21 | 一种盐酸伊托必利分散片组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102600091A CN102600091A (zh) | 2012-07-25 |
CN102600091B true CN102600091B (zh) | 2014-01-29 |
Family
ID=46518122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210086799.1A Active CN102600091B (zh) | 2012-02-13 | 2012-03-21 | 一种盐酸伊托必利分散片组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102600091B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104116718A (zh) * | 2014-05-21 | 2014-10-29 | 丽珠集团丽珠制药厂 | 盐酸伊托必利口服制剂 |
CN109125277B (zh) * | 2018-07-23 | 2020-06-02 | 珠海润都制药股份有限公司 | 一种盐酸伊托必利微片及其制备方法 |
CN115844847B (zh) * | 2022-11-17 | 2023-09-01 | 云南永安制药有限公司 | 一种盐酸伊托必利制剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456148A (zh) * | 2003-03-26 | 2003-11-19 | 北京东方凯恩医药科技有限公司 | 胃肠动力药在制备结肠定位药物组合物中的用途 |
CN101273973B (zh) * | 2007-03-28 | 2010-04-07 | 成都康弘药业集团股份有限公司 | 一种含有枸橼酸莫沙必利的分散片 |
JP5901291B2 (ja) * | 2008-05-01 | 2016-04-06 | リバルシオ コーポレイション | 消化器障害を治療するための組成物および方法 |
CN101816639B (zh) * | 2010-01-15 | 2012-10-10 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利的片剂及其制备方法 |
-
2012
- 2012-03-21 CN CN201210086799.1A patent/CN102600091B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102600091A (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825483B (zh) | 一种丙磺舒缓释片及制备方法 | |
TW200418457A (en) | Oral solid form pharmaceutical and pharmaceutical for the treatment of dysuria | |
CN102600091B (zh) | 一种盐酸伊托必利分散片组合物 | |
US20220401427A1 (en) | Composition containing legoamodipine besylate hydrate and preparation method therefor | |
CN111407730B (zh) | 一种含有利格列汀的药物组合物 | |
CN102114001A (zh) | 一种含有托伐普坦的口服固体制剂 | |
CN102600132A (zh) | 一种含氨磺必利的口服制剂 | |
CN107595798B (zh) | 一种琥珀酸普芦卡必利片剂及其制备方法 | |
CN102228450B (zh) | 尼麦角林胶囊及其生产方法 | |
CN104666274B (zh) | 一种缬沙坦胶囊的制备方法 | |
CN102846575A (zh) | 硝苯地平缓释片及其制备方法 | |
CN101822646B (zh) | 一种盐酸非索非那定口腔崩解片及其制备方法 | |
CN106511291A (zh) | 一种盐酸阿考替胺缓释片剂及其制备方法 | |
CN103007286B (zh) | 一种托伐普坦的固体药物组合物 | |
CN104771400A (zh) | 一种双乙酰大黄酸和小檗碱的口服药物组合物及其应用 | |
CN109925289B (zh) | 地氯雷他定分散片 | |
CN109846843B (zh) | 地氯雷他定口腔崩解片 | |
CN114272219A (zh) | 一种盐酸多奈哌齐片及其制备方法 | |
CN106214637A (zh) | 一种阿立哌唑共研磨物及分散片制备技术 | |
CN109381431B (zh) | 石杉碱甲缓释微丸及其制备方法 | |
CN102309488A (zh) | 一种伊曲康唑药物组合物及其制备方法 | |
CN102151252B (zh) | 格列吡嗪渗透泵型控释片 | |
CN110664761A (zh) | 一种来那度胺药物组合物及其制备方法 | |
CN104706606A (zh) | 一种枸橼酸西地那非片剂及其制备方法 | |
CN104127390B (zh) | 一种多潘立酮片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160809 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200518 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Co-patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210913 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Itopride hydrochloride dispersible tablet composition Effective date of registration: 20220721 Granted publication date: 20140129 Pledgee: Bank of China Limited Weihai Branch Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2022980010828 |